New hope for kids with Tough-to-Treat cancer: trial tests powerful drug combo
Disease control
Ongoing
This study is testing a new treatment approach for children, teens, and young adults whose ALK-positive anaplastic large cell lymphoma has come back or hasn't responded to prior therapy. The treatment combines an immunotherapy drug (nivolumab) with chemotherapy, followed by a ste…
Phase: PHASE2 • Sponsor: New York Medical College • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC